Conotoxins Containing Nonnatural Backbone Spacers: Cladistic-Based Design, Chemical Synthesis, and Improved Analgesic Activity  by Green, Brad R. et al.
Chemistry & Biology
ArticleConotoxins Containing Nonnatural Backbone
Spacers: Cladistic-Based Design, Chemical
Synthesis, and Improved Analgesic Activity
Brad R. Green,1,5 Philip Catlin,1 Min-Min Zhang,1 Brian Fiedler,1 Wendi Bayudan,1,2 Alex Morrison,1
Raymond S. Norton,3 Brian J. Smith,3 Doju Yoshikami,1 Baldomero M. Olivera,1 and Grzegorz Bulaj1,4,*
1Department of Biology, University of Utah, Salt Lake City, UT 84112, USA
2Chaminade University of Honolulu, Honolulu, HI 96816, USA
3The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
4Department of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA
5Present address: Department of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA.
*Correspondence: bulaj@pharm.utah.edu
DOI 10.1016/j.chembiol.2007.02.009SUMMARY
Disulfide-rich neurotoxins from venomous ani-
mals continue to provide compounds with ther-
apeutic potential. Minimizing neurotoxins often
results in removal of disulfide bridges or critical
amino acids. To address this drug-design chal-
lenge, we explored the concept of disulfide-rich
scaffolds consisting of isostere polymers and
peptidic pharmacophores. Flexible spacers,
such as amino-3-oxapentanoic or 6-aminohex-
anoic acids, were used to replace conforma-
tionally constrained parts of a three-disulfide-
bridged conotoxin, SIIIA. The peptide-polymer
hybrids, polytides, were designed based on
cladistic identification of nonconserved loci in
related peptides. After oxidative folding, the
polytides appeared to be better inhibitors of
sodium currents in dorsal root ganglia and
sciatic nerves in mice. Moreover, the polytides
appeared to be significantly more potent and
longer-lasting analgesics in the inflammatory
pain model in mice, when compared to SIIIA.
The resulting polytides provide a promising
strategy for transforming disulfide-rich pep-
tides into therapeutics.
INTRODUCTION
Ranging from spider, scorpion, and cone snail venom
toxins to plant cyclotides, the molecular diversity of disul-
fide-rich peptides can be estimated in millions of unique
molecules [1–4]. These peptides evolved as neurotoxins
to capture prey, for host self-defense, or as neurotrophic
and/or neuromodulatory compounds. As a result of mil-
lions of years of evolution, the bioactive peptides exhibit
high potency and selectivity for their molecular targets,Chemistry & Biology 14making them attractive as pharmacological tools and ther-
apeutic agents (Figure 1A). Mining these exquisite libraries
of disulfide-rich peptides has resulted in such therapeu-
tics as pain-relieving u-MVIIA, the antihemorrhagic drug
aprotinin, and the antidiabetic drug insulin. Many venom
peptides are being tested in preclinical and clinical studies
as analgesic, anticoagulant, antimicrobial, immunosup-
pressant, or anticancer therapeutics [5]. One toxin, zico-
notide, derived from a cone snail venom was approved
by the FDA in 2004 for a treatment of intractable pain [6].
Peptidomimetic approaches have been very effective
for short biopolymers, such as opioid peptides or somato-
statin [7–9]. However, for multiple-disulfide-bridged pep-
tides, an intrinsic problem of reducing molecular size is
a removal of disulfide bridges, often resulting in a loss of
the bioactivity [10, 11]. Rational design and peptidomi-
metic strategies provided compoundswith lower potency,
as documented in the cases of u-conotoxin GVIA [12, 13]
and ShK toxin [14–16]. One successful example of minimi-
zation of a single disulfide-containing peptide by using
structure-based and phage-display methods is a 28 aa
atrial natriuretic peptide (ANP) [17, 18]. Examples of recent
efforts of improving biological stability of conotoxins are
the N-to-C-terminal cyclization of MII or MrIA and the
replacement of disulfides by diselenocystine bridges
[19–21].
To advance engineering technologies for disulfide-rich
peptides, we explored a concept of peptide-based phar-
macophores grafted into crosslinked, polymer-based
scaffolds (Figure 1B). This pseudobiopolymer concept is
encapsulated in the term polytide, a neologism describing
hybrids of nonpeptidic polymers and peptide-based
components. The bioactive conformation of a polytide is
stabilized by disulfide bridges (or other crosslinks, such
as lactams or thioether bridges). To design polytides, we
propose a stepwise replacement of several adjacent
amino acid residues with backbone spacers, such as
PEG spacers or extended-glycine amino acids. The selec-
tion of replacements might be directed by an analysis of
nonconserved loci in closely related sequences of pep-
tides (cladistic analysis), as described previously by our, 399–407, April 2007 ª2007 Elsevier Ltd All rights reserved 399
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Backbone Spacers in ConotoxinsFigure 1. Disulfide-Rich Peptides as
Potential Drugs
(A) Diversity of disulfide-rich scaffolds of thera-
peutically relevant peptides. The names of
peptides currently in preclinical and clinical
development are shown in parentheses.
(B) Concept of polytides. Introduction of iso-
stere backbone spacers into conformationally
constrained peptides produces polymer-
peptide hybrids, polytides. To better illustrate
this concept, two m-conotoxin-based polytides
that differ in a number of backbone spacers are
shown.laboratory [22, 23]. Once successful, such ‘‘backbone
prosthesis’’ replacements may be combined. The term
‘‘protein prosthesis’’ was first proposed by Raines [24,
25]: we would like to extend this term to peptides as
well. In this work, we explored the backbone prosthesis
concept by using conotoxins that block sodium channels
[26–28]. The resulting conotoxin-polymer hybrids ap-
peared to be at least 10-fold more potent analgesics
than the original peptide in the inflammatory pain model
in mice after systemic administration. Our data presented
here show that employing normally flexible spacers in
place of conformationally constrained regions of disul-
fide-bridged peptides is a valid strategy for producing
compounds with a therapeutic potential.
RESULTS
Rational Design of Polytides
The concept of ‘‘backbone prosthesis’’ was inspired by
recently described structure-activity relationships of three
m-conotoxins, SmIIIA, SIIIA, and KIIIA, that belong to a sin-
gle clade of cone snail peptides (Figure 2A) [27]. Despite
naturally occurring central truncations, all three conotox-
ins belonging to a single clade potently blocked Na chan-
nels. KIIIA and SIIIA exhibited comparable activity in
blocking TTX-R and TTX-S sodium channels in amphibian
nerve preparations [27]. Thus, neither the length of the first
loop nor the two N-terminal residues seemed to be critical
for determining interactions with sodium channels. Since
SIIIA contains ‘‘nonessential’’ ZN- at the N terminus, and
2 glycine residues in the first loop, this peptide was se-
lected to test how replacing these residues with backbone
spacers may affect folding and bioactivity. Based on the
above-described cladistic analysis, two analogs were
designed containing two distinct backbone spacers400 Chemistry & Biology 14, 399–407, April 2007 ª2007 Elsevie(Figure 2B). In the first analog, PEG-SIIIA, both ZN- and
-GG- were replaced with amino-3-oxapentanoic acid. In
the second, AHX-SIIIA, 6-aminohexanoic acid was used
instead of amino-3-oxapentanoic acid. The structural var-
iation between SIIIA and the prosthesis-containing ana-
logs in the C-terminal region is evident from comparing
three model structures shown in Figures 2C and 2D. The
region C-terminal to the backbone replacement, however,
maintains a similar conformation to the original SIIIA. In
particular, the residues critical to activity, K11, W12, and
H16 [29], adopt the same spatial arrangement in all three
structures.
Chemical Synthesis and Oxidative Folding
Chemical synthesis of PEG-SIIIA and AHX-SIIIA was
carried out on solid support by using standard Fmoc
protocols. Fmoc-protected amino-3-oxapentanoic acid
or 6-aminohexanoic acid were coupled by using identical
conditions to those used for other amino acids. Cleaved
peptides were purified by using preparative reverse-
phase HPLC. Reduced peptides were added to a buffer
containing 0.1 M Tris/HCl (pH 7.5), 1 mM EDTA, 1 mM
reduced glutathione, and 1 mM oxidized glutathione.
Folding was quenched after an appropriate time, and the
folding mixtures were separated by analytical C18 HPLC.
Representative HPLC separations of the folding reactions
are shown in Figure 3. Folding equilibria for SIIIA and the
hybrids were reached within 10 min. The main folding
products accumulated at 50% for SIIIA, 52% for PEG-
SIIIA, and 28% for AHX-SIIIA. The folded hybrids exhibited
1H NMR spectra similar to that of SIIIA (Figure 3). The am-
ide regions of SIIIA and the analogs were well dispersed,
with the analogs showing even better dispersion than
the parent peptide and lacking minor peaks presumably
arising from minor conformers in SIIIA.r Ltd All rights reserved
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The folded hybrids and SIIIA were tested on TTX-sensitive
(TTXs) sodium currents (INa) in voltage-clamped mouse
dorsal root ganglia (DRG) neurons. Figure 4A illustrates
the block of INa produced by 5 mM of the peptides after
20 min of exposure. SIIIA only blocked 20% of the
TTXs INa, whereas the two hybrids were more active,
blocking 45%–55%. The block by SIIIA and its analogs
was only very slowly reversible. Increasing the concentra-
tion to 25 mM resulted in 65% inhibition for SIIIA and
80% inhibition for the hybrids (Figure 4B). The analogs
were then tested in blocking compound action potentials
(CAPs) in sciatic nerve preparations in mice. Strikingly,
PEG-SIIIA and AHX-SIIIA exhibited faster kinetics in
blocking A-CAPs than SIIIA (Figure 4C). When analogs
with replacements of either the N-terminal or the first
loop -GG- with the PEG spacer were tested, the faster ki-
netics could be mostly accounted for by the N-terminal
PEG moiety. TTX-resistant C-CAPs were not affected by
SIIIA or the hybrids (data not shown).
To evaluate analgesic activity, the analogs were tested
in the inflammatory pain assay in mice (formalin test). Pep-
tides were injected intraperitoneally (i.p.) prior to injection
of formalin. As shown in Figure 5A, all three compounds
were analgesic at doses of 10 nmol per animal (corre-
sponding to 0.7 mg/kg), although both hybrids were
more active in the Phase II response than SIIIA. Since
PEG-SIIIA acted more quickly than SIIIA in blocking A-
CAPs, a time course of the nociceptive response was de-
termined (Figure 5B). At doses of 10 nmol per animal,
PEG-SIIIA exhibited more pronounced and longer-lasting
analgesic activity in the inflammatory phases. We also
observed a significantly faster response for PEG-SIIIA in
the acute response phase, when formalin was injected
30 s or 5 min after the i.p. injection of the compounds.
The analgesic effects were dose dependent, with an
estimated ED50 of 12 nmol per mouse (0.9 mg/kg) for
SIIIA and 0.7 nmol per mouse (0.05 mg/kg) for PEG-SIIIA.
Thus, the PEG-spacer-containing polytide was signifi-
cantly more potent compared to the original conotoxin,
SIIIA.
DISCUSSION
To our knowledge, this work describes the first example of
successful conotoxin engineering in which the resulting
analogs exhibited both improved in vitro and in vivo phar-
macological properties. Replacing peptidic parts of SIIIA
with backbone spacers produced peptide-polymer hy-
brids with reduced molecular size (19 aa instead of 22
aa), and yet with a significantly more potent and longer-
lasting analgesic activity. To our knowledge, we describe
here for the first time that m-conotoxins, such as SIIIA, are
analgesic after systemic administration; this activity is
likely due to blocking of peripheral sodium channels.
These data complement a growing list of diverse analge-
sic conotoxins (reviewed in [30]). Mechanistic aspects of
why the PEG-SIIIA hybrid was a more potent analgesic
than SIIIA are being investigated with more structure-Chemistry & Biology 14, 3activity relationship and pharmacological studies. However,
independent of mechanisms by which backbone prosthe-
sis improved the pharmacological profile of SIIIA, this
work provides the proof-of-concept data for the hypothe-
sis that engineering conotoxins by using backbone
spacers may be a useful strategy by which to develop
therapeutics. Indeed, the very high potency of PEG-SIIIA
(50 mg/kg, i.p.) justifies additional efforts in exploring
this, or related analogs, as an analgesic for treatment of
neuropathic pain.
Although aminohexanoic acid is commonly used in pep-
tides, to the best of our knowledge, this is the first example
of successful introduction of Ahx into a conformationally
constrained peptide. Previously, aminohexanoic acid
was proven useful in engineering centrally truncated ana-
logs of neuropeptide Y [31, 32]. Similarly, introduction of
Ahx into GLP-1 improved its hypoglycemic duration of ac-
tion [33]. In another study, 8-amino-3,6-dioxaoctanoic
acid was used in backbone-substituted analogs of the de-
capeptide antibiotic tyrocidine A [34]. Finally, PEGylation
of peptides and proteins is a commonly used strategy
for improving their therapeutic properties [35]. In contrast
to the previous work, we propose to use diverse flexible
spacers as isosteric replacements of conformationally
constrained parts of disulfide-rich peptides. As illustrated
in Figure 6, such spacers may be of different length or
chemical nature. In fact, there is a growing number of
commercially available spacers compatible with the
solid-phase peptide synthesis using Fmoc chemistry: we
hope that this workmight spur evenmore interest in devel-
oping diverse spacers. We would like to speculate here
that replacing nonessential amino acid residues with dif-
ferent spacers may provide a means to more rational
modifications of bioavailability of the resulting polytides.
Another advantage of this approach is that such isostere
replacements are less likely to compromise the biological
activity, because the bioactive conformation is stabilized
by crosslinks such as the disulfide bridges. Formation of
the native disulfide crosslinks in polytides might be
achieved by either direct oxidative folding, as shown
here, or by orthogonal protection of cysteine residues
[36, 37]. Interestingly, the SIIIA-based polytides main-
tained a high tendency for the efficient oxidative folding,
further emphasizing an important role of the cysteine
patterns in determining folding mechanisms. This is very
encouraging for the synthetic accessibility of polytides
derived from different conotoxins or other disulfide-rich
peptides.
Extending the concept of polytides, the backbone
spacers may be considered for the N-to-C-terminal cycli-
zation, producing cyclotide-polymer hybrids with addi-
tional backbone spacer crosslinks [3]. Similarly, many
peptide inhibitors of proteinases, antimicrobial peptides,
insect toxins, or snake toxins may be amenable to back-
bone prosthesis, making them more attractive drug
candidates compared with peptidomimetics or small mol-
ecules. Since solid-phase synthesis methods have be-
come more and more applicable to larger polypeptides,
backbone spacers may be used in protein engineering99–407, April 2007 ª2007 Elsevier Ltd All rights reserved 401
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Backbone Spacers in ConotoxinsFigure 3. Oxidative Folding of SIIIA and the Peptide-Polymer Hybrids
Folding reactions were carried out in the presence of 0.1 M Tris/HCl (pH 7.5), 1 mM GSSG, and 1 mM GSH at ambient temperature (23C–25C).
Reactions were quenched by acidification, followed by analytical HPLC analysis. The asterisk denotes the folded species characterized by NMR
and used in functional assays. 1H NMR spectra of the folded forms of SIIIA, PEG-SIIIA, and AHX-SIIIA. All spectra were recorded at 600 MHz in
H2O/
2H2O/C
2H3COO
2H (50%/50%/1%) at pH 2.6 and 5C.with either disulfide-rich scaffolds [38] or mini-protein
motifs [39]. It is obvious that more studies will be needed
to validate the broader applicability of polytides, but ourChemistry & Biology 14,present work indicates that such an approach is an effi-
cient strategy for transforming disulfide-rich peptides
into drugs.Figure 2. Design of the m-Conotoxin SIIIA and the Polytides
(A) Cladistic analysis of SmIIIA, SIIIA, and KIIIA. The key structural differences are emphasized by shaded areas.
(B) Structures of SIIIA and two hybrid analogs containing backbone spacers: amino-3-oxapentanoic acid (PEG spacer), yielding PEG-SIIIA; and
6-aminohexanoic acid, yielding AHX-SIIIA.
(C) Model structures of SIIIA, PEG-SIIIA, and AHX-SIIIA. A backbone of eight representative conformations is shown for each analog. The amide back-
bone is gray; the backbone spacers are shown in red, white, and blue.
(D) Superimposition of the backbone atoms of the final structures of SIIIA (dusty-pink), PEG-SIIIA (steel-blue), and AHX-SIIIA (olive-green) from theMD
calculations. The backbone atoms from S9–C20, encompassing the pseudo helical segment, adopt a similar geometry. There are large structural
differences between the three peptides in the N-terminal residues prior to S9, including the backbone replacement groups in the prosthetic deriva-
tives. A closer zoom at the 11–16 region shows that residues K11, W12, and H16 in the three peptides adopt similar positions in the superimposition.
The atoms of the side chains are colored turquoise (carbon) and blue (nitrogen).399–407, April 2007 ª2007 Elsevier Ltd All rights reserved 403
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Backbone Spacers in ConotoxinsFigure 4. SIIIA and the Hybrids Block
Sodium Currents in Mouse Preparations
of DRG Neurons and in the Sciatic Nerve
(A) Representative TTX-sensitive sodium cur-
rents in DRG neurons recorded in the absence
of (control traces, gray) or after an 20 min ex-
posure to 5 mM SIIIA or analogs (black traces).
Each trace represents the average of five re-
sponses. DRG neurons were dissociated and
whole-cell voltage clamped as described in
Experimental Procedures.
(B) Percent block of the peak of the TTX-sensi-
tive sodium current after approximately 20 min
of exposure to either 5 mM (black bars) or
25 mM (gray bars) peptide (mean ± SEM,
n = 3–4).
(C) Block of A-compound action potentials
(TTX-sensitive) in sciatic nerve preparation
from mouse by 1 mM peptide concentrations.SIGNIFICANCE
There is a continuous need to develop drugs derived
from peptide-based natural products, such as neuro-404 Chemistry & Biology 14, 399–407, April 2007 ª2007 Elsevietoxins, antimicrobial peptides, plant peptides, and
others. Traditional structure-based peptidomimetic
approaches are less applicable for these disulfide-
rich peptides, since reducing their molecular size isr Ltd All rights reserved
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Backbone Spacers in ConotoxinsFigure 5. Analgesic Activity of SIIIA and the PEG-SIIIA Hybrid in the Inflammatory Pain Assay in Mouse
(A) Effect of saline (solid square), SIIIA (open triangle), PEG-SIIIA (solid circle), and AHX-SIIIA (open square) on formalin-induced paw licking during
Phases I and II. Treatments were administered intraperitoneally 15 min prior to formalin injection.
(B) Effects of 10 nmol SIIIA or the PEG-SIIIA hybrid on paw licking during Phase II (the combined licking time during 15–30min) at different times before
injection of formalin into a paw. Data are expressed as means ± SEM for four animals.often associated with a removal of stabilizing cross-
links or the removal of critical amino acid residues,
leading to a loss of bioactivity. This work explored
the concept and feasibility of polymer-peptide hy-
Figure 6. Examples of Isostere Spacers Incorporated into
a Peptide Backbone
(A–E) Various F-moc-protected spacers are commercially available.
(A) 5-aminopentanoic acid. (B) 5-amino-3-oxapentanoic acid (PEG
spacer). (C) 6-aminohexanoic acid. (D) 8-aminooctanoic acid. (E)
8-amino-3,6-dioxaoctanoic acid (PEG spacer). Please note that most
spacers shown here have a number of backbone atoms equivalent
to either two or three amino acid residues.Chemistry & Biology 14,brids, in which conformationally constrained, but non-
essential, amino acid residues are replaced with iso-
stere polymeric spacers. The key advantage to this
minimization strategy is that the resulting polytides
maintain the overall size of the molecule and thus
don’t compromise the spatial orientation of key func-
tional residues. Replacing parts of the peptidic back-
bone with various nonpeptidic spacers provides
a means of improving bioavailability by reducing sus-
ceptibility to proteolysis, and reducing hydrogen
bond donors/acceptors (affecting logP values). Al-
though our work provides proof-of-concept data for
the use of conotoxin SIIIA, we hope that this approach
will be explored in many other disulfide-rich peptides
that have a therapeutic potential.
EXPERIMENTAL PROCEDURES
Chemical Synthesis
Peptides were synthesized on amide MBHA resin by using Fmoc
(N-[9-fluorenyl]methoxycarbonyl) chemistry. For coupling of backbone
spacers, the following derivatives were used: Fmoc-aminohexanoic
acid and Fmoc-3-oxapentanoic acid (Fmoc-O1Pen from IRIS Biotech).
The linear forms were purified by reversed-phase HPLC with a semi-
preparative C18 Vydac column (218TP510) in a linear gradient of aceto-
nitrile (in 0.1% TFA). Oxidative folding was performed by resuspending
the linear peptides in 0.01%TFA inwater and injecting this solution into
a buffered solution (0.1 M Tris-HCl [pH 7.5]) containing 1 mM EDTA,
1 mM reduced glutathione, and 1 mM oxidized glutathione. The final
peptide concentration was 20 mM. Folding reactions were monitored
by analytical reversed-phase HPLC separations with a C18 Vydac col-
umn (218TP54) in a linear gradient of acetonitrile. The identity of the
peptides was confirmed by mass spectrometry.399–407, April 2007 ª2007 Elsevier Ltd All rights reserved 405
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Peptide samples (20 nmol) were dried in H2O/
2H2O/C
2H3COO
2H and
resuspended in 250 ml 90% H2O/10%
2H2O/1% C
2H3COO
2H (pH
2.6). One-dimensional 1H NMR spectra were recorded with a Varian
Inova 600 NMR spectrometer. Water suppression was achieved with
an 11-echo scheme. Spectra were recorded at 5Cwith 4096 complex
points and a spectral width of 12 ppm; chemical shifts are referenced
to DSS at 0 ppm.
Molecular Modeling
An initial model of SIIIA was created with the MODELER (6v2) program
[40] by using the solution structure of SmIIIA [29] (PDB code: 1Q2J,
representative structure 13) as a template and by following the proce-
dure described earlier [27]. Backbone prostheses were built into the
initial model of SIIIA by using InsightII (Accelrys, 2000). All structures
were subjected to molecular dynamics (MD) simulation by using the
GROMACS (v3.3.1) package of programs [41] and by applying a similar
approach as had been used to model SIIIA previously [27]. All simula-
tions consisted of an initial minimization of water molecules, followed
by 100 ps of MD with the peptide fixed. After positional restraints
MD, the restraints on the peptide were removed, and MD continued
for an additional 10 ns.
Electrophysiology
DRGs were dissected from adult mice of either sex and dissociated as
described previously [28]. Briefly, dissociated neurons were perfused
with extracellular solution containing (in mM) 35 NaCl, 105 N-methyl-
D-glucammonium-Cl, 3 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, 10 TEA,
and 0.1 CdCl2 (pH 7.3). Recording pipettes contained (in mM) 140
CsF, 10 NaCl, 1 EGTA, and 10 HEPES (pH 7.3). To record TTX-sensi-
tive currents, large DRG neurons (diameter > 35 mm) were selected.
Conotoxins were dissolved in extracellular solution and were applied
to the neurons under study by bath exchange; the bath remained static
throughout the toxin exposure. The membrane potential was held at
80mV, and the sodiumchannelswere activated by a 50ms test pulse
to 20 mV, applied every 30 s. Each test pulse was immediately pre-
ceded by a 50 ms, 120 mV conditioning pulse to remove channel in-
activation. AMultiClamp 700A amplifier (Axon Instruments, Union City,
California) was used, and current signals were low-pass filtered at
3 kHz, digitized at a sampling frequency of 10 kHz, and leak-
subtracted by following a P/6 protocol by using in-house software
written in LabVIEW (National Instruments, Austin, Texas). All experi-
ments were done at room temperature. Compound action potentials
were recorded as described in [30].
Inflammatory Pain Assay
A formalin-induced nociception test in mice was performed as de-
scribed elsewhere [42]. Swiss Webster mice (25–30 g) were placed
in individual open glass cylinders. A total of 15 min prior to intraplantar
injection of 10 ml 4.4% formalin into one hind paw, mice were intraper-
itoneally (i.p.) injected with the tested peptides or saline solution (con-
trol). Mice (two at a time) were observed for 50 min, and paw-licking
time was determined every 5 min in 2 min intervals. The acute (first)
phase of the nociceptive response was quantified within the first
5 min. The inflammatory (second) phase was quantified from 15 to
30 min. For each dose, at least four animals were used. All animal
procedures were carried out according to the approved protocol of
the IUCAC at the University of Utah.
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